In a CMT1A rat model, the overexpression of Pmp22 was markedly reduced by specifically designed ASOs, and this reversed demyelination and axonal loss neuropathy and restored the electrophysiological properties of peripheral neurons, providing a potential treatment for CMT1A [104]. This evidence concerns the gene PMP22 and Charcot-Marie-Tooth disease type 1A.